Rekombinanter IFNA2 Antikörper (PE)

Produktnummer ABIN7867330

Der PE-konjugierte Kaninchen Chimeric anti-IFNA2 Antikörper (Klon 1B7) (ABIN7867330) detektiert spezifisch IFNA2 in FACS. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter IFNA2 Antikörper (PE) (ABIN7867330)

Target: IFNA2 (Interferon, alpha 2 (IFNA2))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser IFNA2 Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS)

Klon: 1B7

Produktdetails anti-IFNA2 Antikörper (PE)

Verwendungszweck: PE-conjugated Anti-IFNA2 antibody(1B7), IgG1 Chimeric mAb

Aufreinigung: Purified from cell culture supernatant by affinity chromatography

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Flow Cyt 1:100

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Liquid PBS with 0.05 %  Proclin300, 1 % BSA

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Store at 2°C-8°C for 6 months

Haltbarkeit: 6 months

Details zu IFNA2

Target: IFNA2 (Interferon, alpha 2 (IFNA2))

Andere Bezeichnung: IFNA2

Hintergrund:

Synonyms: IFNA, IFNA2B, leIF A, IFN-alphaA, IFN-alpha-2

Target Background: This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. The encoded protein is effective in reducing the symptoms and duration of the common cold and in treating many types of cancer, including some hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is thought to be a hallmark of severe COVID-19 and may provide a rationale for a combined therapeutic approach. [provided by RefSeq, Aug 2020]

UniProt: P01563

Pathways: JAK-STAT Signalweg, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Hepatitis C